Condition / Treatment endocrine

Adrenal insufficiency and Corticosteroids

Adrenal insufficiency (AI) is a state of inadequate cortisol availability. Corticosteroids are life‑saving anti‑inflammatory and immunosuppressive drugs that can also suppress the body’s own cortisol production by dampening the hypothalamic‑pituitary‑adrenal (HPA) axis. Understanding how exogenous steroids relate to AI helps patients and clinicians prevent complications, recognize warning signs, and plan safe tapering. Physiologically, systemic corticosteroids provide negative feedback to the HPA axis. With sufficient dose or duration, the pituitary decreases ACTH secretion and the adrenal cortex down‑regulates cortisol synthesis. Suppression risk rises with higher potency and longer‑acting agents (e.g., dexamethasone), evening or continuous dosing, and cumulative exposure. Although oral and injectable forms carry the greatest risk, high‑dose inhaled, potent topical (especially under occlusion or on thin skin), intranasal, epidural, and repeated intra‑articular steroids can also suppress the axis. Clinically meaningful suppression can appear within weeks, and recovery after tapering or discontinuation ranges from weeks to many months, sometimes longer after prolonged therapy. Secondary AI from exogenous steroids differs from primary AI (Addison’s disease). In secondary AI, ACTH is low/normal and aldosterone is typically preserved, so hyperkalemia and salt craving are less common; in primary AI, ACTH is high, hyperpigmentation and mineralocorticoid deficiency are frequent. Shared symptoms include fatigue, weakness, anorexia, weight loss, abdominal pain, and postural dizziness; subtle features may be low mood, low stamina, and exercise intolerance. Red‑flag features of adrenal crisis include severe hypotension, syncope, vomiting with inability to retain medication, fever, confusion, and shock. Diagnosis integrates medication history with testing: an early‑morning serum cortisol can screen, and a cosyntropin (ACTH) stimulation test confirms inadequate adrenal reserve

Updated March 25, 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.

Shared Risk Factors

Higher cumulative dose, longer duration, and greater potency

Strong Evidence

Systemic exposure (including long‑acting agents like dexamethasone) increases negative feedback on the HPA axis, raising risk of secondary AI. Short courses at modest doses pose lower risk; prolonged or repeated courses increase it markedly.

Increases likelihood and depth of secondary adrenal insufficiency and may prolong recovery.
Represents common therapeutic patterns of corticosteroid use for chronic inflammatory disease that elevate suppression risk.

Route and formulation (oral/injected > inhaled/topical > intranasal/ocular)

Moderate Evidence

Oral and parenteral steroids have the highest systemic bioavailability, but high‑dose inhaled (e.g., fluticasone), potent topical under occlusion, epidural, and repeated intra‑articular injections can also suppress the HPA axis.

Secondary AI may emerge even without oral steroids when potent local routes are used chronically.
Certain formulations deliver substantial systemic exposure despite local intent, increasing adverse‑effect risk.

Timing and schedule (evening dosing, continuous vs alternate‑day)

Moderate Evidence

Evening or multiple daily doses blunt the normal early‑morning ACTH surge; alternate‑day and morning dosing may reduce suppression relative to equivalent cumulative doses.

Greater suppression predisposes to symptomatic AI on taper or during stress.
Dosing strategies can balance efficacy with reduced HPA impact.

Drug–drug interactions raising steroid exposure

Strong Evidence

CYP3A4 inhibitors (e.g., ritonavir/cobicistat, azole antifungals, some macrolides) and grapefruit can increase systemic levels of many corticosteroids, heightening suppression risk; inhaled/intranasal fluticasone plus ritonavir is a classic high‑risk pairing.

Can precipitate iatrogenic Cushingoid features followed by profound AI when steroids are withdrawn.
Increases adverse‑effect burden of corticosteroid therapy inadvertently.

Patient vulnerability (frailty, older age, comorbidity) and rapid withdrawal

Emerging Research

Physiologic reserve, intercurrent illness, and abrupt discontinuation influence whether suppressed HPA function becomes clinically apparent.

Greater risk of symptomatic AI and adrenal crisis during illness or abrupt dose reductions.
Therapeutic changes (tapering, surgery, acute infection) can unmask suppression.

Overlapping Treatments

Gradual glucocorticoid taper with clinical and biochemical monitoring

Moderate Evidence
Benefits for Adrenal insufficiency

Allows HPA axis recovery, reducing risk of symptomatic secondary AI and adrenal crisis.

Benefits for Corticosteroids

Maintains disease control while minimizing withdrawal symptoms and rebound inflammation.

Evidence is largely consensus‑based; taper speed individualizes to dose, duration, and relapse risk.

Physiologic hydrocortisone replacement (temporary or ongoing)

Strong Evidence
Benefits for Adrenal insufficiency

Replaces deficient cortisol in confirmed or suspected AI; supports stress coverage.

Benefits for Corticosteroids

Uses a short‑acting agent aligned with diurnal rhythm, enabling stepwise weaning.

Requires education on sick‑day rules and emergency use; mineralocorticoid typically not needed in secondary AI.

Stress‑dosing protocols for intercurrent illness, procedures, or surgery

Strong Evidence
Benefits for Adrenal insufficiency

Prevents adrenal crisis when endogenous production is inadequate.

Benefits for Corticosteroids

Provides safe peri‑illness coverage for patients recently on or currently using steroids.

Dose and route vary by severity of stress and current steroid regimen; follow established guidelines.

Switching to morning dosing and/or shorter‑acting agents when feasible

Moderate Evidence
Benefits for Adrenal insufficiency

Reduces ongoing HPA suppression and may hasten recovery of circadian ACTH drive.

Benefits for Corticosteroids

Maintains therapeutic effect with potentially fewer systemic effects.

Not appropriate for all conditions; clinical response and adherence must be considered.

Steroid‑sparing therapies and delivery optimization

Moderate Evidence
Benefits for Adrenal insufficiency

Lower cumulative steroid exposure reduces AI risk.

Benefits for Corticosteroids

Biologics/DMARDs, spacers with inhaled steroids, lowest effective topical potency/duration help maintain disease control.

Introduce under specialist guidance; monitor for alternative therapy adverse effects.

Patient education, medical alert identification, and emergency hydrocortisone kit where indicated

Moderate Evidence
Benefits for Adrenal insufficiency

Reduces delay to treatment in crisis; empowers effective sick‑day management.

Benefits for Corticosteroids

Supports safe use and discontinuation of corticosteroids across care settings.

Training for patient/caregiver use is essential; ensure continuity across prescribers.

Medical Perspectives

Western Perspective

Western medicine recognizes exogenous corticosteroids as a leading cause of secondary adrenal insufficiency via suppression of the hypothalamic‑pituitary‑adrenal axis. Risk scales with cumulative potency, route, timing, and interacting drugs. Diagnosis hinges on careful medication history plus dynamic testing, and management centers on prevention (dose minimization, tapering) and protection (stress dosing, temporary replacement).

Key Insights

  • Suppression can occur after a few weeks of systemic therapy and after chronic high‑dose local routes (inhaled, potent topical, intra‑articular).
  • Morning cortisol combined with a cosyntropin stimulation test is the standard approach to assess adrenal reserve; ACTH levels help distinguish primary from secondary AI.
  • Recovery of HPA function is variable—often weeks to months, occasionally longer after prolonged therapy.
  • Illness, surgery, or abrupt dose reductions can precipitate adrenal crisis in suppressed patients; stress‑dose protocols markedly reduce this risk.
  • CYP3A4 inhibitors can dramatically increase steroid exposure (notably with inhaled/intranasal fluticasone), intensifying suppression.

Treatments

  • Individualized tapering schedules with slower reductions at physiologic doses
  • Temporary hydrocortisone replacement with sick‑day rules and emergency coverage
  • Perioperative/illness stress dosing based on procedure and severity
  • Use of morning dosing and shorter‑acting agents to respect circadian rhythm
  • Steroid‑sparing strategies (biologics, DMARDs, optimized inhaler technique)
Evidence: Strong Evidence

Sources

  • Broersen LHA et al. J Clin Endocrinol Metab. 2015;100(6):2171-2180.
  • Bornstein SR et al. Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.
  • Bancos I et al. Lancet Diabetes Endocrinol. 2015;3(3):216-226.
  • Foisy MM et al. Clin Pharmacokinet. 2008;47(4):255-267.
  • Habib G. Clin Rheumatol. 2014;33(1):7-13.

Eastern Perspective

Traditional systems frame steroid‑related depletion as a disturbance of vital energy and stress‑response balance. In Traditional Chinese Medicine (TCM), long‑term illness and strong pharmaceuticals may weaken Spleen and Kidney systems, disrupting yin‑yang and daily cycles. Ayurveda interprets chronic stress and potent medicines as aggravating doshas (often Vata) and ojas depletion. Integrative practice focuses on restoring rhythm, resilience, and digestive and sleep health while coordinating with biomedical management.

Key Insights

  • Regularity (sleep–wake, meals) and breath‑mind practices are emphasized to steady the stress response and support daytime energy.
  • Select adaptogenic herbs (e.g., ashwagandha, rhodiola) are traditionally used for fatigue and stress resilience; modern evidence suggests benefits for perceived stress and sleep, not as cortisol substitutes.
  • Acupuncture is applied to harmonize circadian patterns and reduce fatigue and anxiety; small studies support improvements in quality of life.
  • Nutritional emphasis includes warm, easily digested foods, adequate protein, and micronutrient sufficiency (e.g., vitamin D, B‑group) to support recovery.
  • Practitioners caution that certain herbs (e.g., licorice/Gan Cao) can potentiate corticosteroid effects or raise blood pressure and should be used carefully and collaboratively.

Treatments

  • Acupuncture for fatigue, sleep quality, and stress modulation
  • Gentle mind–body practices (qi gong, tai chi, yoga, pranayama) to rebuild stamina
  • Dietary regularity with balanced macronutrients; attention to vitamin D and calcium during/after steroid use
  • Adaptogens such as ashwagandha or rhodiola under clinician supervision
  • Sleep hygiene with consistent bed/wake times to reinforce circadian rhythm
Evidence: Emerging Research

Sources

  • Shergis JL et al. J Altern Complement Med. 2013;19(9):697-709.
  • Lopresti AL et al. Med Open (Oxf). 2019;3(2):e62.
  • Ng QX et al. Complement Ther Med. 2020;52:102452.
  • Zou L et al. Evid Based Complement Alternat Med. 2018;2018:2739059.
  • Zhang Q et al. J Pain Symptom Manage. 2019;57(2):299-310.

Evidence Ratings

Exogenous glucocorticoids suppress the HPA axis and can cause secondary adrenal insufficiency.

Broersen LHA et al. JCEM. 2015;100(6):2171-2180; Bancos I et al. Lancet Diabetes Endocrinol. 2015;3:216-226.

Strong Evidence

Risk of suppression increases with higher dose, longer duration, and longer‑acting agents; evening dosing increases risk.

Bancos I et al. Lancet Diabetes Endocrinol. 2015;3:216-226.

Moderate Evidence

High‑dose inhaled, potent topical, intra‑articular, and epidural steroids can cause clinically relevant HPA suppression.

Broersen LHA et al. JCEM. 2015;100:2171-2180; Habib G. Clin Rheumatol. 2014;33:7-13.

Moderate Evidence

Morning cortisol and cosyntropin stimulation testing reliably assess adrenal reserve and help distinguish primary from secondary AI.

Bornstein SR et al. Endocrine Society Guideline. JCEM. 2016;101:364-389.

Strong Evidence

HPA recovery after long‑term steroid therapy may take months and occasionally more than a year.

Bancos I et al. Lancet Diabetes Endocrinol. 2015;3:216-226.

Moderate Evidence

Stress‑dosing during acute illness or surgery prevents adrenal crisis in suppressed patients.

Bornstein SR et al. Endocrine Society Guideline. JCEM. 2016;101:364-389.

Strong Evidence

CYP3A4 inhibitors (e.g., ritonavir) markedly increase systemic steroid exposure and suppression risk, especially with fluticasone.

Foisy MM et al. Clin Pharmacokinet. 2008;47:255-267.

Strong Evidence

Adaptogens (e.g., ashwagandha) may reduce perceived stress and improve sleep but are not substitutes for corticosteroid replacement.

Ng QX et al. Complement Ther Med. 2020;52:102452; Lopresti AL et al. Med Open (Oxf). 2019;3:e62.

Emerging Research

Western Medicine Perspective

From a western clinical viewpoint, corticosteroids are among the most effective anti‑inflammatory medicines, yet their benefits arise from the same physiology that can precipitate secondary adrenal insufficiency. Exogenous steroids exert negative feedback at the hypothalamus and pituitary, decreasing corticotropin‑releasing hormone and ACTH. Over time, the adrenal cortex down‑regulates steroidogenic enzymes and atrophies, creating a vulnerability: when the exogenous dose is lowered or abruptly stopped, endogenous cortisol may be inadequate, especially during intercurrent illness or surgery. Risk is highest with greater cumulative exposure, evening dosing, long‑acting agents like dexamethasone, and with systemic routes. Importantly, high‑dose inhaled steroids, potent topical applications (particularly under occlusion or on thin skin), repeated intra‑articular injections, and epidural steroids can also suppress the HPA axis. Drug interactions are clinically important; inhibitors of CYP3A4 (e.g., ritonavir, azole antifungals) can sharply increase steroid levels, leading to iatrogenic Cushingoid features followed by profound suppression on withdrawal. Clinically, secondary AI presents with nonspecific but impactful symptoms—fatigue, weakness, anorexia, abdominal discomfort, and orthostatic symptoms—and lacks some features of primary AI such as hyperpigmentation and mineralocorticoid deficiency. Diagnosis begins with a careful medication history, including non‑oral steroids, and proceeds to laboratory evaluation. An early‑morning cortisol offers an initial screen, while a standard 250‑µg cosyntropin stimulation test assesses adrenal reserve; ACTH levels aid in distinguishing secondary from primary etiologies. Management emphasizes preventing crisis and enabling recovery: tapering regimens slow reductions near physiologic doses, switching to morning dosing or shorter‑acting agents where possible, and using steroid‑sparing therapies to reduce cumulative exposure. Patients with suspected suppression require education on stress‑dosing for illness or procedures and may need temporary hydrocortisone replacement, with emergency coverage for vomiting or severe stress. Recovery of HPA function is variable—often weeks to months, occasionally longer after prolonged use—so periodic reassessment guides safe weaning.

Eastern Medicine Perspective

Traditional and integrative frameworks approach steroid‑related fatigue and stress dysregulation through restoration of balance and rhythm. In Traditional Chinese Medicine, prolonged illness and strong drugs can deplete Spleen and Kidney systems, disturbing yin‑yang harmony and daily cycles. Practitioners work to rebuild foundational energy and stabilize the sleep–wake rhythm through acupuncture, qi gong, dietary regularity, and herbal strategies. Ayurveda describes a related pattern of ojas depletion and Vata aggravation under chronic stress or potent medications; care plans focus on nourishment, routine, gentle movement, and mind–body practices such as yoga and pranayama. These traditions do not replace cortisol in biological terms but aim to improve resilience, digestion, sleep, and perceived stress—domains that often worsen during and after corticosteroid therapy. Modern integrative practice blends these insights with biomedical safety. Acupuncture has evidence for reducing fatigue and improving sleep quality in chronic conditions, offering supportive care during recovery. Adaptogenic herbs such as ashwagandha and rhodiola have demonstrated benefits for perceived stress and sleep in small trials; however, they are not substitutes for steroid replacement in proven adrenal insufficiency. Some botanicals, notably licorice (Gan Cao), may potentiate corticosteroid effects or affect blood pressure and should be used cautiously and collaboratively, especially when tapering. Nutrition emphasizes adequate protein, micronutrient sufficiency (including vitamin D and calcium due to steroid‑related bone risk), and steady meal timing. Gentle, progressive activity helps restore stamina without provoking post‑exertional crashes, and consistent bed/wake times reinforce circadian cues. Clear patient education—sick‑day rules, medical alert identification, and recognition of emergency symptoms—bridges traditions and ensures that supportive therapies complement, rather than conflict with, essential medical management.

Sources
  1. Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM. Adrenal insufficiency in corticosteroids users: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171-2180.
  2. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.
  3. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216-226.
  4. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and inhaled/intranasal fluticasone: a review. Clin Pharmacokinet. 2008;47(4):255-267.
  5. Habib G. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2014;33(1):7-13.
  6. Allen DB. Systemic effects of inhaled corticosteroids in children. Pediatrics. 2006;117(2):253-262.
  7. Ng QX, Loke W, Venkatanarayanan N, et al. A systematic review of the use of ashwagandha for stress and anxiety. Complement Ther Med. 2020;52:102452.
  8. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress‑relieving and pharmacological actions of an ashwagandha extract. Medicine (Baltimore). 2019;98(37):e17186.

Related Topics

Health Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.